The HIV Treatment Gap: Estimates of the Financial Resources Needed versus Available for Scale-Up of Antiretroviral Therapy in 97 Countries from 2015 to 2020

1. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015.

2. World Health Organization. Consolidated guidelines on general HIV care and the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013.

3. Joint United Nations Programme on HIV/AIDS. Ambitious treatment targets: writing the final chapter on the AIDS epidemic. Geneva: Joint United Nations Programme on HIV/AIDS; 2014.

4. U.S. President’s Emergency Plan for AIDS Relief. The U.S. President’s Emergency Plan for AIDS Relief and Children’s Investment Fund Foundation launch $200 million Accelerating Children’s HIV/AIDS Treatment Initiative (ACT) to save lives. 6 August 2014. Available: http://www.pepfar.gov/press/releases/2014/230334.htm. Accessed 22 October 2015.

5. The Vancouver Consensus. From the International AIDS Society Conference, 2015. Available: http://vancouverconsensus.org/. Accessed 22 October 2015.

6. Joint United Nations Programme on HIV/AIDS. The gap report. Geneva: Joint United Nations Programme on HIV/AIDS; 2014.

7. AIDSinfo Online Database. Available: http://www.aidsinfoonline.org/devinfo/libraries/aspx/Home.aspx. Accessed 15 July 2015.

8. Stover J, Gopalappa C, Mahy M, Doherty MC, Easterbrook PJ, Weiler G, et al. The impact and cost of the 2013 WHO recommendations on eligibility for antiretroviral therapy. AIDS. 2014;28:S225–S230. doi: 10.1097/QAD.0000000000000235 24849482

9. Stover J, Korenromp EL, Blakley M, Komatsu R, Viisainen K, Bollinger L, et al. Long-term costs and health impact of continued global fund support for antiretroviral therapy. PLoS ONE. 2011;6:e21048. doi: 10.1371/journal.pone.0021048 21731646

10. Schwartländer B, Stover J, Hallett T, Atun R, Avila C, Gouws E, et al. Towards an improved investment approach for an effective response to HIV/AIDS. Lancet. 2011;377:2031–2041. doi: 10.1016/S0140-6736(11)60702-2 21641026

11. Joint United Nations Programme on HIV/AIDS. Fast-track: ending the AIDS epidemic by 2030. Geneva: Joint United Nations Programme on HIV/AIDS; 2014.

12. Global Fund to Fight AIDS, Tuberculosis and Malaria. Fourth replenishment (2014–2016): needs assessment. Geneva: Global Fund to Fight AIDS, Tuberculosis and Malaria; 2013.

13. Wafula F, Agweyu A, Macintyre K. Trends in procurement costs for HIV commodities: a 7-year retrospective analysis of global fund data across 125 countries. J Acquir Immune Defic Syndr. 2014;65:e134–e139. doi: 10.1097/QAI.0000000000000053 24189152

14. Vassall A, Remme M, Watts C, Hallett T, Siapka M, Vickerman P, et al. Financing essential HIV services: a new economic agenda. PLoS Med. 2013;10:e1001567. doi: 10.1371/journal.pmed.1001567 24358028

15. Doherty K, Essajee S, Penazzato M, Holmes C, Resch S, Ciaranello A. Estimating age-based antiretroviral therapy costs for HIV-infected children in resource-limited settings based on World Health Organization weight-based dosing recommendations. BMC Health Serv Res. 2014;14:201. doi: 10.1186/1472-6963-14-201 24885453

16. Joint United Nations Programme on HIV/AIDS. Spectrum/EPP. Geneva: Joint United Nations Programme on HIV/AIDS. Available: http://www.unaids.org/en/dataanalysis/datatools/spectrumepp2013. Accessed 22 October 2015.

17. World Health Organization. Consolidated strategic information guidelines for HIV in the health sector. Geneva: World Health Organization; 2015.

18. Curry LA, Byam P, Linnander E, Andersson KM, Abebe Y, Zerihun A, et al. Evaluation of the Ethiopian Millennium Rural Initiative: impact on mortality and cost-effectiveness. PLoS ONE. 2013;8:e79847. doi: 10.1371/journal.pone.0079847 24260307

19. Pandey A, Sahu D, Bakkali T, Reddy D, Venkatesh S, Kant S, et al. Estimate of HIV prevalence and number of people living with HIV in India 2008–2009. BMJ Open. 2012;2:e000926. doi: 10.1136/bmjopen-2012-000926 23028110

20. Bashorun A, Nguku P, Kawu I, Ngige E, Ogundiran A, Sabitu K, et al. A description of HIV prevalence trends in Nigeria from 2001 to 2010: what is the progress, where is the problem? Pan Afr Med J. 2014;18 (Suppl 1):3. doi: 10.11694/pamj.supp.2014.18.1.4608 25328622

21. Stover J, Brown T, Marston M. Updates to the Spectrum/Estimation and Projection Package (EPP) model to estimate HIV trends for adults and children. Sex Transm Infect. 2012;88 (Suppl 2):i11–i16. doi: 10.1136/sextrans-2012-050640 23172341

22. Yiannoutsos CT, Johnson LF, Boulle A, Musick BS, Gsponer T, Balestre E, et al. Estimated mortality of adult HIV-infected patients starting treatment with combination antiretroviral therapy. Sex Transm Infect. 2012;88 (Suppl 2):i33–i43. doi: 10.1136/sextrans-2012-050658 23172344

23. Structured Data. RiskAMP version 4.72 professional edition [computer program]. San Francisco: Stuctured Data; 2015.

24. Joint United Nations Programme on HIV/AIDS. AIDSinfo Online Database [database]. Geneva: Joint United Nations Programme on HIV/AIDS. Available: http://www.aidsinfoonline.org/devinfo/libraries/aspx/Home.aspx. Accessed 15 July 2015.

25. Shafer R. Rationale and uses of a public HIV drug-resistance database. J Infect Dis. 2006;194:S51–S58. 16921473

26. World Health Organization. Antiretroviral medicines in low- and middle-income countries: forecasts of global and regional demand for 2013–2016. Geneva: World Health Organization; 2014.

27. Hong SY, Jonas A, Dumeni E, Badi A, Pereko D, Blom A, et al. Population-based monitoring of HIV drug resistance in Namibia with early warning indicators. J Acquir Immune Defic Syndr. 2010;55:27. doi: 10.1097/QAI.0b013e3181f5376d 20838224

28. Scott CA, Iyer HS, McCoy K, Moyo C, Long L, Larson BA, et al. Retention in care, resource utilization, and costs for adults receiving antiretroviral therapy in Zambia: a retrospective cohort study. BMC Public Health. 2014;14:296. doi: 10.1186/1471-2458-14-296 24684772

29. Assefa Y, Kiflie A, Tesfaye D, Mariam DH, Kloos H, Edwin W, et al. Outcomes of antiretroviral treatment program in Ethiopia: retention of patients in care is a major challenge and varies across health facilities. BMC Health Serv Res. 2011;11:81. doi: 10.1186/1472-6963-11-81 21501509

30. Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DHJ, Gregson J, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet. 2012;380:1250–1258. doi: 10.1016/S0140-6736(12)61038-1 22828485

31. Fox MP, Van Cutsem G, Giddy J, Maskew M, Keiser O, Prozesky H, et al. Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. J Acquir Immune Defic Syndr. 2012;60:428. doi: 10.1097/QAI.0b013e3182557785 22433846

32. Auld AF, Mbofana F, Shiraishi RW, Sanchez M, Alfredo C, Nelson LJ, et al. Four-year treatment outcomes of adult patients enrolled in Mozambique’s rapidly expanding antiretroviral therapy program. PLoS ONE. 2011;6:e18453. doi: 10.1371/journal.pone.0018453 21483703

33. Clinton Health Access Initiative. The state of the antiretroviral drug market in low- and middle-income countries: ARV market report. Boston: Clinton Health Access Initiative; 2013.

34. World Health Organization. Transaction prices for antiretroviral medicines from 2010 to 2013: Global Price Reporting Mechanism. Geneva: World Health Organization; 2013.

35. Perriëns JH, Habiyambere V, Dongmo-Nguimfack B, Hirnschall G. Prices paid for adult and paediatric antiretroviral treatment by low-and middle-income countries in 2012: high, low or just right? Antivir Ther. 2014;19:39–47. doi: 10.3851/IMP2899 25310645

36. Médecins Sans Frontières. Untangling the web of antiretroviral price reductions, 17th edition. Geneva: Médecins Sans Frontières; 2014.

37. Nachega JB, Mugavero MJ, Zeier M, Vitória M, Gallant JE. Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs. Patient Prefer Adherence. 2011;5:357–367. doi: 10.2147/PPA.S22771 21845035

38. Nakakeeto ON, Elliott BV. Antiretrovirals for low income countries: an analysis of the commercial viability of a highly competitive market. Global Health. 2013;9:6. doi: 10.1186/1744-8603-9-6 23410145

39. Clinton Health Access Initiative. 2014 antiretroviral (ARV) ceiling price list. Boston: Clinton Health Access Initiative; 2014.

40. Godlevskiy D, Volgina A, Golovin S, Girchenko P, Skvortsov A. To treat or not to treat? ARV treatment procurement and provision in Russia. Saint Petersburg: ITPCru; 2012.

41. Meyer-Rath G, Brennan A, Long L, Ndibongo B, Technau K, Moultrie H, et al. Cost and outcomes of paediatric antiretroviral treatment in South Africa. AIDS. 2013;27:243–250. doi: 10.1097/QAD.0b013e32835a5b92 23014517

42. Dutta A, Perales N, Semeryk O, Balakireva O, Aleksandrina T, Leshchenko O, et al. Lives on the line: funding needs and impacts of Ukraine’s national HIV/AIDS program, 2014–2018. Washington (District of Columbia): Palladium; 2014.

43. Dutta A, Perales N, Silva R, Cirera i Criville L. Estimated resource needs and impact of Mozambique’s Plano Estrategico do Sector Saude, 2014–2019. Washington (District of Columbia): Palladium; 2014.

44. Perales N, Dutta A, Maina T. Resource needs for the Kenya health sector strategic and investment plan: analysis using the OneHealth Tool. Washington (District of Columbia): Palladium; 2015.

45. Médecins Sans Frontières. How low can we go? Pricing for HIV viral load testing in low- and middle-income countries. Geneva: Médecins Sans Frontières; 2013.

46. Kahn JG, Marseille E, Moore D, Bunnell R, Were W, Degerman R, et al. CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study. BMJ. 2011;343:d6884. doi: 10.1136/bmj.d6884 22074713

47. World Health Organization. Technical and operational considerations for implementing HIV viral load testing. Geneva: World Health Organization; 2014.

48. UNITAID. HIV/AIDS diagnostics technology landscape. 4th edition. Vernier (Switzerland): UNITAID; 2014.

49. Roche. Roche launches Global Access Program for HIV viral load testing. 26 September 2014. Basel: Roche.

50. Clinton Health Access Initiative. Annual report 2014. Boston: Clinton Health Access Initiative; 2013.

51. Wu G, Zaman MH. Low-cost tools for diagnosing and monitoring HIV infection in low-resource settings. Bull World Health Organ. 2012;90:914–920. doi: 10.2471/BLT.12.102780 23284197

52. Setty MKHG Hewlett IK. Point of care technologies for HIV. AIDS Res Treat. 2014;2014:497046. doi: 10.1155/2014/497046 24579041

53. Tagar E, Sundaram M, Condliffe K, Matatiyo B, Chimbwandira F, Chilima B, et al. Multi-Country Analysis of Treatment Costs for HIV/AIDS (MATCH): facility-level ART unit cost analysis in Ethiopia, Malawi, Rwanda, South Africa and Zambia. PLoS ONE. 2014;9:e108304. doi: 10.1371/journal.pone.0108304 25389777

54. Galárraga O, Wirtz V, Figueroa-Lara A, Santa-Ana-Tellez Y, Coulibaly I, Viisainen K, et al. Unit costs for delivery of antiretroviral treatment and prevention of mother-to-child transmission of HIV. Pharmacoeconomics. 2011;29:579–599. doi: 10.2165/11586120-000000000-00000 21671687

55. Riviere C, Faust E, Miller T, Beck EJ, Baruwa E, Severe P, et al. Superior outcomes and lower outpatient costs with scale-up of antiretroviral therapy at the GHESKIO Clinic in Port-au-Prince, Haiti. J Acquir Immune Defic Syndr. 2014;66:e72–e79. doi: 10.1097/QAI.0000000000000200 24984189

56. Health Policy Project, Côte d’Ivoire Ministry of Health. Estimating the cost of HIV treatment for adults, children, and pregnant women in Cote d’Ivoire. Washington (District of Columbia): Futures Group; 2015.

57. Moreland S, Namisango E, Paxton A, Powell RA. The costs of HIV treatment, care, and support services in Uganda. Available: http://www.cpc.unc.edu/measure/publications/tr-13-94. Chapel Hill (North Carolina): MEASURE Evaluation; 2013.

58. Marseille E, Giganti MJ, Mwango A, Chisembele-Taylor A, Mulenga L, Over M, et al. Taking ART to scale: determinants of the cost and cost-effectiveness of antiretroviral therapy in 45 clinical sites in Zambia. PLoS ONE. 2012;7:e51993. doi: 10.1371/journal.pone.0051993 23284843

59. Scott CA, Iyer H, Bwalya DL, McCoy K, Meyer-Rath G, Moyo C, et al. Retention in care and outpatient costs for children receiving antiretroviral therapy in Zambia: a retrospective cohort analysis. PLoS ONE. 2013;8:e67910. doi: 10.1371/journal.pone.0067910 23840788

60. Larson BA, Bii M, Henly-Thomas S, McCoy K, Sawe F, Shaffer D, et al. ART treatment costs and retention in care in Kenya: a cohort study in three rural outpatient clinics. J Int AIDS Soc. 2013;16:18026. doi: 10.7448/IAS.16.1.18026 23305696

61. Aliyu HB, Chuku NN, Kola-Jebutu A, Abubakar Z, Torpey K, Chabikuli ON. What is the cost of providing outpatient HIV counseling and testing and antiretroviral therapy services in selected public health facilities in Nigeria? J Acquir Immune Defic Syndr. 2012;61:221–225. 22820805

62. Obure CD, Sweeney S, Darsamo V, Michaels-Igbokwe C, Guinness L, Terris-Prestholt F, et al. The Costs of delivering integrated HIV and sexual reproductive health services in limited resource settings. PLoS ONE. 2015;10:e0124476. doi: 10.1371/journal.pone.0124476 25933414

63. Duong AT, Kato M, Bales S, Do NT, Minh Nguyen TT, Thanh Cao TT, et al. Costing analysis of national HIV treatment and care program in Vietnam. J Acquir Immune Defic Syndr. 2014;65:e1–e7. doi: 10.1097/QAI.0b013e3182a17d15 23846564

64. Meyer-Rath G. National ART cost model, South Africa. Johannesburg: Health Economics and Epidemiology Research Office; 2015.

65. Meyer-Rath G, Over M. HIV treatment as prevention: modelling the cost of antiretroviral treatment—state of the art and future directions. PLoS Med. 2012;9:e1001247. doi: 10.1371/journal.pmed.1001247 22802731

66. Callahan K, Gunda A, Phanitsiri S, Kaur M, Mgomezulu L, Tagar E, et al. Analysis of the change in facility-level ART unit costs after implementation of the new WHO treatment guidelines in Malawi [abstract]. 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 19–22 Jul 2015; Vancouver, Canada.

67. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva: World Health Organization; 2010.

68. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access. Geneva: World Health Organization; 2010.

69. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach. Geneva: World Health Organization; 2010.

70. World Health Organization. Global update on HIV treatment 2013: results, impact and opportunities. Geneva: World Health Organization; 2013.

71. Nguyen LT, Tran BX, Tran CT, Le HT, Van Tran S. The cost of antiretroviral treatment service for patients with HIV/AIDS in a central outpatient clinic in Vietnam. Clinicoecon Outcomes Res. 2014;6:101–108. doi: 10.2147/CEOR.S57028 24591843

72. Diabaté S, Zannou DM, Geraldo N, Chamberland A, Akakpo J, Ahouada C, et al. Antiretroviral therapy among HIV-1 infected female sex workers in Benin: a comparative study with patients from the general population. World J AIDS. 2011;1:94.

73. Menzies NA, Berruti AA, Blandford JM. The determinants of HIV treatment costs in resource limited settings. PLoS ONE. 2012;7:e48726. doi: 10.1371/journal.pone.0048726 23144946

74. U.S. President’s Emergency Plan for AIDS Relief. 2014 report on costs of treatment in the President’s Emergency Plan for AIDS Relief. Washington ((District of Columbia): U.S. President’s Emergency Plan for AIDS Relief; 2014.

75. Simmons B, Hill A, Ford N, Ruxrungtham K, Ananworanich J. Prices of second-line antiretroviral treatment for middle-income countries inside versus outside sub-Saharan Africa. J Int AIDS Soc. 2014;17 (Suppl 3):19604.

76. International Monetary Fund. IMF eLibrary data: gross domestic product, deflator, index [database]. Available: http://elibrary-data.imf.org/FindDataReports.aspx?d=33061&e=169393. Accessed 22 October 2015.

77. Global Fund to Fight AIDS, Tuberculosis and Malaria. Price and Quality Reporting [database]. Geneva: Global Fund to Fight AIDS, Tuberculosis and Malaria; 2015.

78. Global Fund to Fight AIDS, Tuberculosis and Malaria. Report of the Secretariat’s Grant Approvals Committee: GF/B33/ER03 Board Decision. Geneva: Global Fund to Fight AIDS, Tuberculosis and Malaria; 2015.

79. Birx, DL. PEPFAR 3.0 overview: right things in the right places, right now for epidemic control and an AIDS-free generation. PEPFAR Scientific Advisory Board (SAB) Introductory Teleconference. 30 April 2015. Available: http://www.pepfar.gov/documents/organization/244554.pdf. Accessed 28 October 2015.

80. Unidad Nacional de Gestión de Medicamentos e Insumos. Reevaluation of the HIV financing gap in the framework of SUGEMI planning for 2013. Santo Domingo (Dominican Republic): Unidad Nacional de Gestión de Medicamentos e Insumos; 2013.

81. International Council of AIDS Service Organizations, Global Forum on MSM and HIV. Punishing success? Explanation of band 4 of the Global Fund to Fight AIDS, Tuberculosis and Malaria and its implications for civil society and key populations. Toronto: International Council of AIDS Service Organizations; 2014.

82. Abdullaev T, Konstantinov B, Hamelmann C. Legal and regulatory frameworks for antiretroviral medicines and treatment in selected countries of the Commonwealth of Independent States: a sub-regional analytical report including Belarus, Kazakhstan, Russia, Tajikistan, and Uzbekistan. New York: United Nations Development Programme; 2014.

83. Barbada Carasso K, Chee G, Cico A, Quyen DH, Cam Tu P, Sitruk A. Options for integrating procurement and supply chain systems for ARVs, methadone, and anti-tuberculosis drugs in Vietnam. Bethesda (Maryland): Health Finance and Governance Project; 2014.

84. Bekker L-G, Venter F, Cohen K, Goemare E, Van Cutsem G, Boulle A, et al. Provision of antiretroviral therapy in South Africa: the nuts and bolts. Antivir Ther. 2014;19 (Suppl 3):105–116. doi: 10.3851/IMP2905 25310359

85. Ripin DJ, Jamieson D, Meyers A, Warty U, Dain M, Khamsi C. Antiretroviral procurement and supply chain management. Antivir Ther. 2014;19:79–89. doi: 10.3851/IMP2903 25310145

86. Sennamose O. Government spends P1.3 billion on ARVs. Botswana Daily News. 29 Aug 2013.

87. The Jakarta Post. Govt urged to drop plan on ARV budget cut. The Jakarta Post. 22 May 2014.

88. Tjitemisa K. MOHSS awards multi-million tenders. New Era. 8 Aug 2014.

89. South African Press Association. Health Department awards R10 billion ARV tender. Times Live. 24 December 2014.

90. Hunger J, Derrick D, Korah G. Increasing domestic investment [presentation]. Geneva: Global Fund to Fight AIDS, Tuberculosis and Malaria; 2014.

91. Hastuti EB. ARV programs in Indonesia: advantages, challenges and the way forward [abstract]. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 30 Jun–3 Jul 2013; Kuala Lumpur, Malaysia.

92. Ngadiman SB. Financing ARV—experience from Malaysia [abstract]. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 30 Jun–3 Jul 2013; Kuala Lumpur, Malaysia.

93. Bhakeecheep D. ART program management under universal health coverage [abstract]. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; 30 Jun–3 Jul 2013; Kuala Lumpur, Malaysia.

94. Health Policy Project. Health Policy Project helps generate US$30 million for strategic health commodities including ARVs in Kenya. Washington (District of Columbia): Palladium; 2015.

95. Instituto Nacional de Luta Contra a SIDA. Plano de acção 2015 revisto. Luanda (Angola): Instituto Nacional de Luta Contra a SIDA; 2015.

96. RITES. Tenders: World Bank tenders—supply tenders. Gurgaon (India): RITES. Available: http://new.rites.com/index.php?page=page&id=65&name=Supply%20Tenders%20&mid=73. Accessed 11 May 2015.

97. Lin RL, Auton M, editors. The Global Fund: ARV acquisition strategy [presentation]. The Global Fund–PEPFAR ARV Supplier Conference; 24–25 Jun 2014; Dubai. Available: http://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0CB0QFjAAahUKEwjno9ugjeXIAhUBdx4KHTlyCW8&url=http%3A%2F%2Fwww.theglobalfund.org%2Fdocuments%2Fp4i%2Fevents%2FP4I_2014-06-25-GF-PEPFAR-ARV-Supplier-Conference-Introduction_Presentation_en%2F&usg=AFQjCNGgSBAtzSWYFnERpQ4cWGSLLb1Kpw&sig2=BoOmkSxbd14Z4g2DsaI1Sg. Accessed 28 October 2015.

98. Kavanagh M, Thorp M. PEPFAR’s declining investment in HIVAIDS treatment. Available: http://healthaffairs.org/blog/2011/11/29/pepfars-declining-investment-in-hivaids-treatment/. Health Affairs Blog. 29 November 2011.

99. Joint United Nations Programme on HIV/AIDS. Global AIDS response progress reporting 2013: construction of core indicators for monitoring the 2011 UN Political Declaration on HIV/AIDS. Geneva: Joint United Nations Programme on HIV/AIDS; 2013.

100. World Health Organization. Database on procurement of HIV and hepatitis products. Geneva: World Health Organization. Available: http://www.who.int/hiv/pub/amds/hiv-hep-procurement-database/en/. Accessed 29 May 2015.

101. Beyrer C, Sullivan PS, Sanchez J, Dowdy D, Altman D, Trapence G, et al. A call to action for comprehensive HIV services for men who have sex with men. Lancet. 2012;380:424–438. doi: 10.1016/S0140-6736(12)61022-8 22819663

102. Beyrer C, Malinowska-Sempruch K, Kamarulzaman A, Kazatchkine M, Sidibe M, Strathdee SA. Time to act: a call for comprehensive responses to HIV in people who use drugs. Lancet. 2010;376:551–563. doi: 10.1016/S0140-6736(10)60928-2 20650515

103. Kerrigan D, Wirtz A, Baral S, Stanciole A, Butler J, Oelrichs R, et al. The global HIV epidemics among sex workers. Washington (District of Columbia): The World Bank; 2012.

104. Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, et al. How should HIV programmes respond to evidence for the benefits of earlier treatment initiation? A combined analysis of twelve mathematical models. Geneva: World Health Organization; 2013.

105. Braithwaite RS, Nucifora KA, Toohey C, Kessler J, Uhler LM, Mentor SM, et al. How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa? AIDS. 2014;28:S73–S83. doi: 10.1097/QAD.0000000000000110 24468949

106. Barnhart M, Shelton JD. ARVs: the next generation. Going boldly together to new frontiers of HIV treatment. Glob Health Sci Pract. 2015;3:1–11. doi: 10.9745/GHSP-D-14-00243 25745115

107. Spreen WR, Margolis DA, Pottage JC. Long-acting injectable antiretrovirals for HIV treatment and prevention. Current Opin HIV AIDS. 2013;8:565–571. doi: 10.1097/COH.0000000000000002 24100877

108. Heger M. Trials challenging HIV drug doses could usher in huge cost cuts. Nat Med. 2013;19:953. doi: 10.1038/nm0813-953 23921730

109. Mdege ND, Chindove S, Ali S. The effectiveness and cost implications of task-shifting in the delivery of antiretroviral therapy to HIV-infected patients: a systematic review. Health Policy Plan. 2012;28:223–236. doi: 10.1093/heapol/czs058 22738755

110. Callaghan M, Ford N, Schneider H. A systematic review of task-shifting for HIV treatment and care in Africa. Hum Resour Health. 2010;8:8–16. doi: 10.1186/1478-4491-8-8 20356363

111. Waning B, Kaplan W, King AC, Lawrence DA, Leufkens HG, Fox MP. Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases. Bull World Health Organ. 2009;87:520–528. 19649366